Vida Health's 2-Drug Mandate Before $1,000/Month Zepbound Sparks Regulatory Risk
Startup Vida Health’s cost-control strategy—forcing patients to try two off-label generics before covering pricey GLP-1s—is drawing backlash from doctors and could invite regulatory scrutiny, threatening the obesity telehealth sector.